This
technology describes a T cell hybridoma specific for, and reactive to, human
myelin oligodendrocyte glycoprotein (MOG)-35-55. The T-cell hybridoma is
positive for D3(+) and CD4(+) cells and negative for CD8(-) cells, expresses TCR
BV8/AV11 and AV17 genes, and produces IL-2, IFN-y and TNF-a Th1 cytokines upon
concanavalin A or MOG peptide stimulation. The MOG-35-55 peptide-specific T-cell
hybridoma is a novel, humanized T-cell reagent can induce experimental
autoimmune encephalomyelitis (EAE) in mice and can be recognized by T cells from
patients with multiple sclerosis. It is useful for standardized biological
screening as well as activation pathways induced by MOG-35-55 peptide associated
with T-cell ligands or presented by
antigen presenting cell (APC).

Market
Overview

- Multiple sclerosis is a debilitating
neurological autoimmune disease with a higher incidence in women

-
More than 400,000 Americans affected

- About 2.1 million people are affected
worldwide

- MS patients develop clinical signs at
about age 30, and require increasing care as their disease
progresses and
their

productivity
decreases over the duration of their normal lifespan

- There is no cure for MS. Currently,
treatments include disease modifying agents that attempt to
reduce disease
activity

and progression, symptom treatment, and methods to improve
life functions

Licensing
Opportunity

The
technology is available for licensing on a non-exclusive basis for internal
use.